Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2026mAbsOpen Access

Subcutaneous drug delivery of high concentration antibody products – part 2: formulation, device options, and clinical bridging strategies for patient-centric commercial presentations

View Full Paper
Ask AI
Bookmark
Share

Authors

IGIndrajit GhoshSDSuyash DeodharHGHiten Gutka

Discussion

Loading...

Member takes

Overview

Review discusses formulation and delivery options for subcutaneous biologics, emphasizing patient-centered strategies.

Key Points

  • This review aims to analyze the development of subcutaneous combination drug products with a focus on patient-centered approaches.
  • Analyzed various delivery platforms including pre-filled syringes, auto-injectors, infusion pumps, and on-body systems.
  • Examined formulation strategies for high-dose delivery via increased concentration or volume.
  • Presented case studies to illustrate clinical bridging strategies.
  • Identified key factors influencing selection of delivery formats based on patient usability and therapeutic performance.
  • Showed that innovative formulations can significantly impact subcutaneous delivery capabilities.
  • Highlighted the importance of bridging the gap between laboratory innovations and real-world clinical applications.

Cite This Study

Ghosh et al. (2026) studied this question.

synapsesocial.com/papers/6a28ffc76f82f25be989c984https://doi.org/10.1080/19420862.2026.2680773
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Addressing the needs for large-volume subcutaneous drug delivery: the case for on-body wearable injectors2026
  2. 2Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development2025 · 11 citations
  3. 3Subcutaneous Administration of Antibody–Drug Conjugates: Current Challenges, Emerging Opportunities, and Future Perspectives2026
  4. 4Advancements and challenges in large molecule drug delivery and devices for patient-centric care2026
  5. 5Challenging the myths of subcutaneous delivery: An industry expert perspective2026